Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data
1. ATAI and Beckley report Phase 2b trial success for BPL-003. 2. BPL-003 showed significant efficacy in reducing depression symptoms. 3. Private placement of 18.3 million shares raised $50 million for ATAI. 4. Transaction expected to finalize in late 2025, contingent on trial success. 5. ATAI stock surged 28.3% in premarket trading following the news.